16 / 33
First Subsequent Systemic Therapy
Pembrolizumab, n (%)
a
N = 51
Chemotherapy, n (%)
a
N = 100
Crossover to pembrolizumab
NA
82 (82.0)
Anti–PD-1 outside of crossover
2 (3.9)
12 (12.4)
Nivolumab
0
9 (9.0)
Pembrolizumab
2 (3.9)
3 (3.0)
Platinum doublet
42 (82.4)
2 (2.0)
Carboplatin + pemetrexed ± bevacizumab
15 (29.4)
b
0
Carboplatin + paclitaxel ± bevacizumab
9 (17.6)
c
1 (1.0)
Carboplatin + gemcitabine
9 (17.6)
1 (1.0)
Cisplatin + pemetrexed
6 (11.8)
0
Cisplatin + gemcitabine
2 (3.9)
0
Platinum + pemetrexed
1 (2.0)
0
Other
7 (13.7)
4 (4.0)
Cisplatin
2 (3.9)
0
Cabozantinib
1 (2.0)
0
Carboplatin
2 (3.9)
0
Cytarabine
1 (2.0)
0
Pemetrexed + bevacizumab
1 (2.0)
0
Pemetrexed
0
2 (2.0)
Docetaxel
0
1 (1.0)
Paclitaxel
0
1 (1.0)
a
Percentages calculated out of the number of patients who received subsequent therapy.
b
1 patient received carboplatin + pemetrexed + bevacizumab.
c
3 patients received carboplatin +
paclitaxel + bevacizumab. Data cutoff: July 10, 2017.
Rina Hui
et al, COSA 2017